Baker Bros. Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Baker Bros. Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-14,466	Closed	-$2.08M	–	116
2017 Q4	$2.08M	Hold	14,466	–	–	0.02%	98
2017 Q3	$2.38M	Hold	14,466	–	–	0.02%	94
2017 Q2	$1.96M	Hold	14,466	–	–	0.02%	88
2017 Q1	$2.79M	Hold	14,466	–	–	0.02%	81
2016 Q4	$2.04M	Hold	14,466	–	–	0.02%	93
2016 Q3	$2.11M	Hold	14,466	–	–	0.02%	94
2016 Q2	$1.46M	Hold	14,466	–	–	0.02%	107
2016 Q1	$1.94M	Hold	14,466	–	–	0.02%	101
2015 Q4	$2.88M	Hold	14,466	–	–	0.02%	94
2015 Q3	$2.29M	Hold	14,466	–	–	0.02%	101
2015 Q2	$5.9M	Hold	14,466	–	–	0.05%	72
2015 Q1	$6.64M	Buy	14,466 +8,193	+131%	+$3.53M	0.06%	69
2014 Q4	$3.52M	Hold	6,273	–	–	0.04%	83
2014 Q3	$3.29M	Hold	6,273	–	–	0.04%	77
2014 Q2	$4.38M	Buy	6,273 +2,333	+59%	+$1.09M	0.05%	75
2014 Q1	$1.82M	Sell	3,940 -149	-4%	-$75.5K	0.02%	90
2013 Q4	$1.41M	Buy	+4,089	New	+$1.13M	0.02%	85

Other funds holding KPTI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Baker Bros. Advisors's KPTI Position: Q1 2018 in Review

Baker Bros. Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2018, closing a stake of 14,466 shares — an estimated $2.08M sold.

Baker Bros. Advisors first reported a position in KPTI in Q4 2013 and held it in 17 quarters. The position peaked at $6.64M in Q1 2015. 88 funds tracked by Wall St. Rank hold KPTI as of Q1 2018.

Baker Bros. Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2018 after selling out during the quarter.
Baker Bros. Advisors sold 14,466 Karyopharm Therapeutics shares in Q1 2018, an estimated $2.08M.
Baker Bros. Advisors first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 17 quarters.
Baker Bros. Advisors's Karyopharm Therapeutics position peaked at $6.64M in Q1 2015.
88 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2018.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.